The impact of transfer learning on 3D deep learning convolutional neural network segmentation of the hippocampus in mild cognitive impairment and Alzheimer disease subjects.

Journal: Human brain mapping
Published Date:

Abstract

Research on segmentation of the hippocampus in magnetic resonance images through deep learning convolutional neural networks (CNNs) shows promising results, suggesting that these methods can identify small structural abnormalities of the hippocampus, which are among the earliest and most frequent brain changes associated with Alzheimer disease (AD). However, CNNs typically achieve the highest accuracy on datasets acquired from the same domain as the training dataset. Transfer learning allows domain adaptation through further training on a limited dataset. In this study, we applied transfer learning on a network called spatial warping network segmentation (SWANS), developed and trained in a previous study. We used MR images of patients with clinical diagnoses of mild cognitive impairment (MCI) and AD, segmented by two different raters. By using transfer learning techniques, we developed four new models, using different training methods. Testing was performed using 26% of the original dataset, which was excluded from training as a hold-out test set. In addition, 10% of the overall training dataset was used as a hold-out validation set. Results showed that all the new models achieved better hippocampal segmentation quality than the baseline SWANS model (p  < .001), with high similarity to the manual segmentations (mean dice [best model] = 0.878 ± 0.003). The best model was chosen based on visual assessment and volume percentage error (VPE). The increased precision in estimating hippocampal volumes allows the detection of small hippocampal abnormalities already present in the MCI phase (SD = [3.9 ± 0.6]%), which may be crucial for early diagnosis.

Authors

  • Erica Balboni
    Health Physics Unit, Azienda Ospedaliera di Modena, Modena, Italy.
  • Luca Nocetti
    Health Physics Unit, Azienda Ospedaliera di Modena, Modena, Italy.
  • Chiara Carbone
    Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Nicola Dinsdale
    Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Maurilio Genovese
    Neuroradiology Unit, Azienda Ospedaliera di Modena, Modena, Italy.
  • Gabriele Guidi
    Medical Physics Department, Az. Ospedaliero-Universitaria di Modena, Italy; Physics Department, University of Bologna, Italy. Electronic address: guidi.gabriele@policlinico.mo.it.
  • Marcella Malagoli
    Neuroradiology Unit, Azienda Ospedaliera di Modena, Modena, Italy.
  • Annalisa Chiari
    Neuroradiology Unit, Azienda Ospedaliera di Modena, Modena, Italy.
  • Ana I L Namburete
    Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, United Kingdom. Electronic address: ana.namburete@eng.ox.ac.uk.
  • Mark Jenkinson
    Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, UK.
  • Giovanna Zamboni
    Wellcome Centre for Integrative Neuroimaging, Oxford Centre for Functional MRI of the Brain, Nuffield Department of Clinical Neurosciences, University of Oxford, UK; Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford, UK.